Navigation Links
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
Date:6/28/2008

MOUNTAIN VIEW, Calif., June 28 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (IV) DHE. The study results were among six posters relating to the MAP0004 program that the Company presented at the American Headache Society 50th Annual Scientific Meeting in Boston, MA.

In this receptor pharmacology study, MAP0004 stimulated receptors that relieve migraine at levels comparable to IV DHE, but did not activate receptors associated with side effects frequently seen with IV DHE. In addition, MAP0004 did not affect receptors that have a role in regulating pulmonary function.

"The selective binding of MAP0004 at receptors associated with migraine rather than those associated with side effects offers a mechanistic hypothesis for the favorable safety and efficacy profile of MAP0004 compared to IV DHE that we have observed in our initial clinical studies," said Thomas A. Armer, Ph.D., Chief Scientific Officer of MAP Pharmaceuticals. "The absence of negative effects of MAP0004 on pulmonary function in asthmatic subjects observed in a Phase 2 study is also important because migraine and asthma are frequently co-morbid conditions."

MAP0004 is designed to be self-administered by patients at home via MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In Phase 2 studies with migraneurs and with asthmatics, treatment with MAP0004 was well-tolerated, with no serious adverse events reported. Drug-induced nausea was very low and migraine-associated nausea also decreased with treatment.

The Company presented a poster summariz
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
6. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
7. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
8. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 28, 2015 Research and Markets ( ... "North America Open System MRI Market - Growth, Trends ... offering. The key players in the industry ... Siemens Healthcare and Toshiba Medical Systems ... replacing CT because of its higher sensitivity and use ...
(Date:5/29/2015)... , May 28, 2015 Research ... addition of Jain PharmaBiotech,s new report "Cardiovascular ... to their offering. Drug delivery to ... other systems because of the anatomy and physiology ... nutrients to all organs of the body. Drugs ...
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
Breaking Medicine Technology:North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3LifeNet Health to add more than 160 jobs in 2015 2
... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... today that it has commenced vaccination of,volunteers for ... pandemic,influenza H5N1 vaccine. The Phase II clinical trial ... and efficacy of the pandemic,influenza H5N1 vaccine. The ...
... 11 ImClone Systems,Incorporated (Nasdaq: IMCL ... BMY ),today announced that a Phase III ... chemotherapy (vinorelbine plus cisplatin),met its primary endpoint ... in patients with advanced non-small cell lung ...
Cached Medicine Technology:Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine 2ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 2ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 3ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 4ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 5ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 6ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 7ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 8ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 9
(Date:5/30/2015)... 2015 On Sunday, June 14, 2015, ... – Jefferson Health will host Journey to Survivorship, a ... speaker, brunch and resources for cancer survivors and their ... the event will be Kathy LaTour, editor-at-large for Cure ... then again in 2007, LaTour provides a unique perspective ...
(Date:5/30/2015)... Chicago, Il (PRWEB) May 30, 2015 ... for Clinical Oncology (ASCO) Annual Meeting 2015 show activity ... cancer, in one case specifically against brain metastases and ... HER2+ breast cancer patients. , "I am thrilled to ... patient in her early 40s. She didn't have any ...
(Date:5/30/2015)... May 30, 2015 On Thursday, ... Dr. Charles Simone and Dr. Evan Alley both ... ‘Meet the Mesothelioma Experts’ series. The interview was ... mesothelioma centers of excellence. Drs. Simone and Alley ... Mary Hesdorffer, with whom they discussed the mesothelioma ...
(Date:5/30/2015)... 30, 2015 Nicole Blodgett, Vice ... Income Associate (DIA) designation to further her expertise ... is designed for insurance advisors, health care professionals, ... knowledge and expertise associated with the risk and ... designation is only the latest accomplishment in Nicole's ...
(Date:5/30/2015)... 2015 San Luis Obispo insurance ... offering a free analysis and consultation for anyone interested ... Disability Awareness Month, which was created by the non-profit ... United States such as Polk recognize the proclamation, and ... the possibility of disability, as well as the often-overlooked ...
Breaking Medicine News(10 mins):Health News:Abington Hospital to Host Cancer Survivorship Event 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2
... efforts,to mobilize opposition to the Bush Administration,s planned $770 ... benefits in the,year ahead, the Coalition to Protect Senior ... to go on record publicly opposing,cuts to seniors, Medicare ... an especially negative impact on rural America,s nursing home,care., ...
... KALAMAZOO, Mich., May 28 Stryker Corporation,(NYSE: SYK ... following,investor conferences:, June 11, 2008 - 9:00 ... LLC Biotechnology and Medical Technology Conference New ... a.m. Pacific Time Goldman Sachs Twenty-Ninth Annual Global ...
... experts don,t endorse use of the drugs to combat ... painkillers called non-steroidal anti-inflammatory drugs (NSAIDs) appear to reduce ... medication in the class works better than the others, ... the largest of its kind, contradicts some previous studies ...
... -- WASHINGTON, DC) The American College of ... announced today a multi-year partnership to jointly sponsor ... Fla., March 2831, 2009, during ACC.09, the ACCs ... cardiovascular meeting. This will be the beginning ...
... FDA,s Janet Woodcock, MD, Provides,Practical Guidance on New ... that the Food and,Drug Administration (FDA) has new ... manufacturers can be required to develop,comprehensive risk assessment ... To help pharmaceutical companies, consultants and other drug ...
... Health Care Association: Rising Energy and Food Costs, Existing,Medicaid ... Texas, May 28 A new national study,analyzing how ... rural America,s seniors and nursing homes finds Texas will ... Texas Health Care,Association (THCA) to warn that yet another ...
Cached Medicine News:Health News:National Frontline Caregiver Coalition: Bush Administration Medicare Cuts 'Will Undercut Rural America's Nursing Home Care' 2Health News:National Frontline Caregiver Coalition: Bush Administration Medicare Cuts 'Will Undercut Rural America's Nursing Home Care' 3Health News:Stryker to Present at Investor Conferences 2Health News:Ibuprofen No Better at Reducing Alzheimer's Risk 2Health News:Ibuprofen No Better at Reducing Alzheimer's Risk 3Health News:ACC and CRF announce partnership on ACC's Innovation in Intervention: i2 Summit 2Health News:FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management 2Health News:New Study of Bush Medicare Cuts: Texas' Rural Seniors, Nursing Homes 2nd Hardest Hit in Nation 2Health News:New Study of Bush Medicare Cuts: Texas' Rural Seniors, Nursing Homes 2nd Hardest Hit in Nation 3
Angled 13.5 mm adjustable blades. Teeth in lower jaws fit into holes in upper jaws. Grooves in lower jaw for passage of suture needles. Round knurled handle with polished finish....
Multi-curved shafts with straight blades and longitudinal serrations. Slide lock and serrated handle with polished finish. Blade length: 27 mm....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Smooth pointed tips open to 3.0 mm. Straight shafts. Cross action. Round handle....
Medicine Products: